Dr Anne-Ulrike Trendelenburg

Working group 1 leader
Management Committee
Core Group
Novartis
  • Switzerland

Anne-Ulrike is Director and leads the Cambridge (US) group of the Muscle program (FiP) at the Novartis Institutes for Biomedical Research. She studied Pharmacy at the University of Freiburg in Germany. She obtained her PhD in Pharmacology and Toxicology at the Albert Ludwigs University, Freiburg, Germany, followed by a position as Assistant Scientist and Lecturer, Department of Pharmacology and Toxicology at University of Freiburg, Germany. In 2001, she completed her state doctorate and obtained the “venia legendi” in Pharmacology and Toxicology at the Albert Ludwigs University, Freiburg, Germany. 

In 2001, she joined the Novartis Ophthalmics Research, later Ophthalmology Disease Area (DA), Novartis Institutes for Biomedical Research, as labhead and, was promoted to Scientific Expert Pharmacology/KTC in 2002 and to Unit Head Target and Lead Discovery in 2004. She led Research Unit, project teams of drug discovery and exploratory projects, managed various internal and external collaborations and represented DA in Council, International Project Team (IPT) and cross-functional boards. In 2005, she completed a Master’s Certificate in Project Management, ESI/George Washington University, USA. Anne-Ulrike joined newly formed Muscle FiP in July 2005, where she has established muscle labs and projects as well as various collaborations with internal departments and supported build-up of Muscle FiP. In 2011, she relocated to NIBR Cambridge where she leads the Cambridge group of Muscle Diseases. 

She represented Novartis in the Endostem consortium from 2011-2015 and leads WG1 of the COST action MouseAge.

Anne-Ulrike has investigated muscle ageing, atrophy and hypertrophy pathways, including myostatin and cytokine signalling and leads various target identification and drug discovery projects. One major focus of her recent research are mechanisms of impaired muscle regeneration in age-related conditions, particularly sarcopenia and cellular senescence. 

Tags: